Здоровье без побочных эффектов

17. House of Commons Health Committee. The Influence of the Pharmaceutical Industry. Fourth Report of Session 2004–05. Available online at: www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf (accessed 26 April 2005).

18. Graham D.J. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA. 2006; 296: 1653–6.

19. Jüni P., Nartey L., Reichenbach S., et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004; 364: 2021–9.

20. Garattini S. Confidentiality. Lancet. 2003; 362: 1078–9.

21. Union of Concerned Scientists. FDA Scientists Pressured to Exclude, Alter Findings; scientists fear retaliation for voicing safety concerns. 2006 July 20.

22. Psaty B.M., Burke S.P. Institute of Medicine on drug safety. N Engl J Med. 2006; 355: 1753–5.

23. Anonymous. Institute of Medicine urges reforms at FDA. Lancet. 2006; 368: 1211.

24. Strom B.L. How the US drug safety system should be changed. JAMA. 2006; 295: 2072–5.

25. Abramson J. Overdo$ed America: the broken promise of American medicine. New York: HarperCollins; 2004.

26. United States General Accounting Office. Food and Drug Administration: effect of user fees on drug approval times, withdrawals, and other agency activities. Sept 2002.

27. Reuters. Danish drugmaker Lundbeck A/S and Japanese partner Takeda Pharmaceutical Co have submitted a new antidepressant for regulatory approval in the United States. 2012 Oct 2.

28. Avorn J., Shrank W. Highlights and a hidden hazard – the FDA’s new labeling regulations. N Engl J Med. 2006; 354: 2409–11.

29. Letter from FDA scientists to President Barrack Obama. 2009 Apr 2. Available online at: http://gaia-health.com/articles201/000201-letter.pdf (accessed 11 Nov 2012).

30. Lichtblau E., Shane S. Vast FDA effort tracked e-mails of its scientists. New York Times. 2012 July 14.

31. Rosenberg M. Former FDA reviewer speaks out about intimidation, retaliation and marginalizing of safety. Truthout. 2012 July 29.

32. Brynner R., Stephens T. Dark Remedy: the impact of thalidomide and its revival as a vital medicine. New York: Perseus Publishing; 2001.

33. Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry. Lanham: Rowman & Littlefi eld; 2008.

34. Sibbison J.B. USA: dirty work in the drug industry. Lancet. 1991; 337: 227.

35. Wikipedia. Duilio Poggiolini. Available online at: http://en.wikipedia.org/wiki/Duilio_Poggiolini (accessed 10 November 2012).

36. Abbott A. Italian health sector in disarray following more scandals. Nature. 1993; 364: 663.

37. Medawar C., Hardon A. Medicines out of control? Antidepressants and the conspiracy of goodwill. Netherlands: Aksant Academic Publishers; 2004.

38. Day M. Italian police arrest drug offi cials over alleged falsifi cation of data. BMJ. 2008; 336: 1208–9.

39. Pfizer memoranda, 24 and 26 April 1989.

40. Grill M. Kranke Geschäfte: wie die Pharmaindustrie uns manipuliert. Hamburg: Rowohlt Verlag; 2007.

41. Relman A.S., Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.

42. Ismail M. Drug Lobby Second to None: how the pharmaceutical industry gets its way in Washington. The Center for Public Integrity. 2005 July 7.

43. Bass A. Side Effects – a prosecutor, a whistleblower, and a bestselling antidepressant on trial. Chapel Hill: Algonquin Books; 2008.

44. Gøtzsche P.C., Jørgensen A.W. Opening up data at the European Medicines Agency. BMJ. 2011; 342: d2686.

45. Anonymous. FDA more transparent than EMEA. Prescrire International. 2002; 11: 98.

46. Garattini S., Bertele V. How can we regulate medicines better? BMJ. 2007; 335: 803–5.

47. Kranish M. Drug industry costs doctor top FDA post. Boston Globe. 2002 May 27.

48. Goozner M. The $800 Million Pill: the truth behind the cost of new drugs. Berkeley: University of California Press; 2005.

49. McClellan M.B. Speech before First International Colloquium on Generic Medicine. Available online at: www.fda.gov/oc/speeches/2003/genericdrug0925.html (accessed 18 February 2008).

50. Carpenter D., Zucker E.J., Avorn J. Drug-review deadlines and safety problems. N Engl J Med. 2008; 358: 1354–61.

51. Carpenter D. Drug-review deadlines and safety problems (authors’ reply). N Engl J Med. 2008; 359: 96–8.

52. Moore T.J., Cohen M.R., Furberg C.D. Serious adverse drug events reported to the Food and Drug Administration, 1998–2005. Arch Intern Med. 2007; 167: 1752–9.